Replies to post #248713 on Biotech Values

[DewDiligence]

Biocon’s Eylea biosimilar will launch in US market in 2H26, pursuant to litigation settlement with REGN:

https://www.prnewswire.com/news-releases/biocon-biologics-secures-market-entry-date-for-yesafili-an-interchangeable-biosimilar-to-eylea-in-the-us-302428884.html

[DewDiligence]

FDA approves 20-week Eylea-HD dosing_during_second_year_for wet AMD and DME:

https://www.globenewswire.com/news-release/2026/04/02/3267657/0/en/EYLEA-HD-aflibercept-Approved-by-FDA-as-First-and-Only-Injectable-Anti-VEGF-with-Dosing-Intervals-Up-to-5-Months-for-Wet-Age-related-Macular-Degeneration-wAMD-and-Diabetic-Macular-.html